PGN-EDODM1: Administered by intravenous (IV) infusion
Study summary
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Participant has completed a prior study with PGN-EDODM1
Exclusion Criteria:
* Abnormal laboratory tests at screening considered clinically significant by the Investigator
* Use of an investigational drug (other than PGN-EDODM1), device, or product, within 30 days or 5 half-lives of the study drug (whichever is longer) prior to study entry
Primary outcome measure(s)
Safety and tolerability as assessed by number of participants with Adverse Events (AEs) — Baseline through Week 108
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.